|
|||||
|
|
Cediranib,a pan-VEGFR inhibitor,and olaparib,a PARP inhibitor,in combination therapy for high grade serous ovarian cancer |
|
| Authors: | S. Percy Ivy Joyce F. Liu Jung-Min Lee Ursula A. Matulonis Elise C. Kohn |
| Affiliation: | 1. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USAivyp@ctep.nci.nih.gov;3. Gynecologic Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA;4. Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA;5. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA |
| Abstract: | |
| Keywords: | Germline deleterious BRCA1/2 mutation chemical and contextual synthetic lethality poly(adenosine diphosphate-ribose) polymerase inhibitor DNA repair defect homologous recombination repair high grade serous ovarian cancer vascular endothelial growth factor receptor inhibitor |